Veterans face disproportionately high rates of lung cancer, often diagnosed too late for the most effective treatments. In this episode, NAVREF CEO Rashi Romanoff and RWJBarnabas Health pulmonologist Dr. Michael Nicholson explore how CyPath Lung, a non-invasive, home-based sputum test powered by AI, can transform lung cancer screening and early detection for veterans.

In this episode, a multidisciplinary panel of pulmonology, thoracic surgery and oncology experts discusses real-world lung nodule cases and how noninvasive CyPath® Lung testing can help refine risk stratification. The panel explores when testing may support decisions to pursue biopsy, when a negative result may help avoid unnecessary invasive procedures, and how multidisciplinary collaboration can improve the management of patients with indeterminate lung nodules. The experts also look ahead to the evolving role of noninvasive testing in lung nodule management.

In this episode, a multidisciplinary panel - an interventional pulmonologist, thoracic surgeon, and medical oncologist - explores the growing challenge of indeterminate lung nodules in high-risk patients. The experts discuss the limitations of current risk-stratification approaches and how CyPath® Lung, a noninvasive sputum-based test, can provide objective information to help clinicians better assess the likelihood of malignancy and guide decisions about follow-up, surveillance, or biopsy.

In this episode, the pulmonologists participating in a roundtable discussion go beyond the challenges of pulmonary nodule management to discuss how CyPath® Lung is being integrated into real-world clinical workflows. The panel explores patient anxiety and stigma, when to biopsy and when not to, and how a noninvasive sputum-based test can risk stratify and help guide next steps for patients with indeterminate pulmonary nodules.

The discussion also takes a deeper look at the science behind CyPath® Lung and offers compelling patient cases—including a smoker ultimately diagnosed with Stage I lung cancer and a heart transplant candidate with a difficult-to-access pulmonary nodule.

A panel of pulmonologists discuss their use of CyPath® Lung in clinical practice as part of a comprehensive approach to lung cancer risk assessment, pulmonary nodule management, and surveillance of lung cancer survivors post-treatment. A key theme that emerges from the conversation is how CyPath® Lung enhances clinical confidence in determining appropriate next steps for patients at risk for lung cancer.

Moderator: Gordon Downie, MD, PhD bioAffinity Technologies Chief Medical Officer

Panelists:

· Sai Karan Vamsi Guda, DO Interventional pulmonologist with Texas Pulmonary & Critical Care Consultants

· Michael Nicholson, DO Pulmonologist and critical care specialist with RWJBarnabas Health Medical Group

· Gregory White, MD Pulmonologist at CHRISTUS Trinity Clinic